Topotecan

Generic Name
Topotecan
Brand Names
Hycamtin, Potactasol, Topotecan Hospira
Drug Type
Small Molecule
Chemical Formula
C23H23N3O5
CAS Number
123948-87-8
Unique Ingredient Identifier
7M7YKX2N15
Background

An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.

Indication

用于小细胞肺癌（SCLC）和一线治疗失败的晚期转移性卵巢癌。

Associated Conditions
Acute Myeloid Leukemia, Ewing's Sarcoma, Refractory Neuroblastoma, Metastatic Rhabdomyosarcoma, Recurrent Stage IVB Cervical Cancer, Refractory CNS lymphoma, Refractory CNS malignancy, Refractory, metastatic Ovarian cancer, Relapsed Platinum Sensitive Small Cell Lung Cancer (SCLC)
Associated Therapies
-
Clinical Trials
Related News

Higher Dose Weekly Topotecan In The Treatment Of Patients With Extensive Stage Small-Cell Lung Cancer

Phase 2
Completed
Conditions
Small Cell Lung Cancer
Carcinoma, Small Cell
Interventions
Drug: Topotecan
First Posted Date
2006-02-20
Last Posted Date
2012-12-10
Lead Sponsor
SCRI Development Innovations, LLC
Target Recruit Count
38
Registration Number
NCT00294190
Locations
🇺🇸

Watson Clinic Center for Cancer Care and Research, Lakeland, Florida, United States

🇺🇸

Consultants in Blood Disorders and Cancer, Louisville, Kentucky, United States

🇺🇸

Northeast Georgia Medical Center, Gainesville, Georgia, United States

and more 10 locations

Active Symptom Control Alone Or In Combination With Oral Topotecan In Patients With Relapsed Resistant Small Cell Lung Cancer

Phase 3
Completed
Conditions
Lung Cancer, Small Cell
First Posted Date
2006-01-13
Last Posted Date
2013-04-15
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
141
Registration Number
NCT00276276
Locations
🇬🇧

GSK Investigational Site, Sutton, Surrey, United Kingdom

Intravenous Weekly Topotecan In Subjects With Recurrent Or Persistent Endometrial Cancer

First Posted Date
2005-12-21
Last Posted Date
2012-07-11
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
70
Registration Number
NCT00267488
Locations
🇭🇺

GSK Investigational Site, Debrecen, Hungary

A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced Solid Tumors

Phase 1
Completed
Conditions
Lung Cancer, Small Cell
Interventions
Drug: topotecan
First Posted Date
2005-12-01
Last Posted Date
2017-11-14
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
107
Registration Number
NCT00259935
Locations
🇳🇱

GSK Investigational Site, Utrecht, Netherlands

Weekly IV Topotecan and Cisplatin With Radiation in Cervical Carcinoma

Phase 2
Completed
Conditions
Cervical Cancer
Interventions
Drug: Topotecan
Drug: Cisplatin
First Posted Date
2005-11-23
Last Posted Date
2018-02-05
Lead Sponsor
University of California, Irvine
Target Recruit Count
12
Registration Number
NCT00257816
Locations
🇺🇸

Chao Family Comprehensive Cancer Center, Orange, California, United States

A Phase I Study of Oral Topotecan as a Radiosensitizing Agent in Patients With Rectal Carcinoma

First Posted Date
2005-09-22
Last Posted Date
2013-12-23
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
31
Registration Number
NCT00215956
Locations
🇺🇸

H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States

Topotecan in Combination With Docetaxel in Refractory and/or Advanced Solid Tumors

Phase 1
Completed
Conditions
Cancer
First Posted Date
2005-09-19
Last Posted Date
2009-01-23
Lead Sponsor
SCRI Development Innovations, LLC
Target Recruit Count
20
Registration Number
NCT00193570

Weekly Topotecan Therapy in Patients With Ovarian Cancer

Phase 2
Terminated
Conditions
Ovarian Cancer
First Posted Date
2005-09-19
Last Posted Date
2006-09-13
Lead Sponsor
Weill Medical College of Cornell University
Target Recruit Count
32
Registration Number
NCT00194935
Locations
🇺🇸

Weill Medcial College of Cornell University, New York, New York, United States

Weekly Topotecan in the First-line Treatment of Elderly Patients With Small Cell Lung Cancer

Phase 2
Completed
Conditions
Lung Cancer
First Posted Date
2005-09-19
Last Posted Date
2010-07-28
Lead Sponsor
SCRI Development Innovations, LLC
Target Recruit Count
40
Registration Number
NCT00193401

Weekly Topotecan in the Second-Line Treatment of Small Cell Lung Cancer

Phase 2
Completed
Conditions
Lung Cancer
First Posted Date
2005-09-19
Last Posted Date
2010-07-28
Lead Sponsor
SCRI Development Innovations, LLC
Target Recruit Count
100
Registration Number
NCT00193388
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy